Misoprostol Shortage Update: What Patients Need to Know in 2026

Misoprostol — a medication used for everything from NSAID ulcer prevention to labor induction and medical abortion — has had a complicated availability story since 2022. If you're wondering whether it's still in shortage and what that means for your prescription, this update covers everything you need to know heading into 2026.

Current Shortage Status: 2026

As of early 2026, misoprostol is not classified as an active drug shortage by the FDA or ASHP. The American Society of Health-System Pharmacists reports that all marketed presentations of misoprostol tablets are currently available, including Pfizer's brand-name Cytotec and Greenstone (Viatris) generic versions in both 100 mcg and 200 mcg strengths.

However, "officially available" doesn't mean "easy to find at your corner pharmacy." A significant gap remains between national supply levels and local pharmacy availability — and that's the real story for most patients in 2026.

What Happened: The 2022 Surge in Demand

Misoprostol was a relatively low-profile generic drug for decades before June 2022, when the U.S. Supreme Court overturned Roe v. Wade in Dobbs v. Jackson Women's Health Organization. Suddenly, clinics and providers began stockpiling misoprostol — particularly in states where abortion remained legal — anticipating both increased demand and potential supply chain disruptions.

ANI Pharmaceuticals, one of the generic manufacturers, reported that demand surged significantly. Planned Parenthood clinics ordered up to a year's supply of misoprostol at once. Despite these pressures, supply generally held — but the demand spike exposed just how thin the margins were in this market.

Lupin's Discontinuation and Its Impact

One development that reduced available supply was Lupin's discontinuation of their generic misoprostol tablets. While ASHP notes this did not cause a formal shortage (Pfizer and Greenstone/Viatris continue to supply the market), fewer generic manufacturers means a narrower supply base. If either remaining generic supplier experienced a manufacturing disruption, it could quickly tip into an actual shortage.

State Laws Are Creating Access Gaps — Even Without a True Shortage

For many patients in 2026, the access problem isn't a supply shortage — it's a dispensing problem driven by state law. Several states have passed or are attempting to pass laws that restrict how and when pharmacists can dispense misoprostol, particularly for reproductive health uses.

Louisiana, for example, passed legislation attempting to classify mifepristone and misoprostol as controlled dangerous substances. Several other states have enacted laws creating legal uncertainty for pharmacists who fill misoprostol prescriptions for abortion-related purposes. The result is a patchwork of access that varies dramatically from state to state — and sometimes from pharmacy to pharmacy within the same state.

Why Some Patients Still Can't Fill Their Prescriptions in 2026

Even in areas where misoprostol is legally dispensable and technically in supply, some patients report difficulty. Common reasons include:

Low stocking levels at individual pharmacies — historically low retail demand means minimal stock on hand

Pharmacist refusals based on conscience clauses in states that permit them

Inconsistent chain pharmacy policies that differ by location within the same state

Legal uncertainty leading pharmacies in certain states to simply stop carrying the medication

What Patients Can Do Right Now

If you're struggling to find misoprostol, the most efficient step is to use medfinder to check multiple pharmacies simultaneously. medfinder calls pharmacies near you and reports back which ones have your medication in stock — saving you the frustration of repeated hold times and incorrect information.

You can also review our comprehensive guide on how to find misoprostol in stock near you for additional strategies including independent pharmacies, compounding options, and prescriber assistance.

The misoprostol situation in 2026 is manageable — but only if you know where to look and how to search efficiently.